Ish Khanna, PhD - Co-founder and Chief Executive Officer
Dr. Khanna has over 28 years of pharmaceutical industry experience with proven record of success in advancing drug molecules from “concept to clinic and market” He has held Technical and Executive Leadership positions in pharmaceutical companies (Pfizer, Pharmacia, Searle, Dr. Reddy’s Labs, Kareus Therapeutics). Dr. Khanna is experienced in building balanced discovery portfolio comprising of First in Class, Best in Class and Drug Repositioning. Dr. Khanna’s areas of expertise include medicinal chemistry, PK/PD correlations of drug molecules, IP strategies, lead optimization strategies and novel therapeutics for pain, inflammation, cardiovascular and metabolic diseases. He is a co-inventor and co-author of over 100 patents and peer reviewed science publications. Dr. Khanna is co-inventor of celecoxib and multiple clinical agents across therapeutics.
Sivaram Pillarisetti, PhD - Co-founder
Dr. Pillarisetti has over 23 years of experience in research in Academia and Industry. Most recently he was head of research at Kareus Therapeutics and prior to that he was the Vice President of Research at Reddy US Therapeutics and Dr Reddy’s Laboratories (DRL). At DRL he headed the biology department and was managing activities from discovery to clinic. He has successfully brought several drug molecules from concept to clinic. Key accomplishments include three candidates in Phase 1/2 and several in preclinical development. He has been conducting research in the cardiovascular and metabolic diseases for over 18 years. Prior to Reddy US Therapeutics/Dr Reddy Laboratories, Dr. Pillarisetti had held faculty appointments at Columbia University and the North Shore-Long Island Jewish Health System in New York, where he established a peptide discovery program for Angion Biotech. His areas of expertise include Inflammation, Pain and Metabolic diseases. He is the author of over 50 research papers and review articles and inventor on several issued patents. Dr. Pillarisetti had been an investigator of the American Heart association (1996-99) and is a current member of the American Diabetes association and a fellow of the American Heart Association.
Jeri El-Hage, PhD - Regulatory Toxicology expert. Ex-FDA senior reviewer for pharmacology/toxicology. About 25 years experience with18-years at FDA.
Francois Caussade, PhD - In Vivo Pharmacology expert. Over 29 years experience developing innovative models for chronic pain.
Bob Ings, PhD - DMPK expert. Over 40 years senior leadership positions (Roche, Daiichi, Amgen, Pharmacia, Servier)
Richard Timmer, PhD - Dr Timmer is an experienced business development/intellectual property professional and entrepreneur in the biopharmaceutical sector with more than 25 years in the chemical and life sciences industries (Morris, Manning & Martin, LLP, Chemcore therapeutics, AIM Therapeutics and Dr Reddy Labs).